A glucose sensor protein for continuous glucose monitoring.

Biosens Bioelectron

Biomedical Engineering Program, College of Engineering, University of Arkansas, 203 Engineering Hall, Fayetteville, AR 72701, USA.

Published: December 2010

In vivo continuous glucose monitoring has posed a significant challenge to glucose sensor development due to the lack of reliable techniques that are non- or at least minimally-invasive. In this proof-of-concept study, we demonstrated the development of a new glucose sensor protein, AcGFP1-GBPcys-mCherry, and an optical sensor assembly, capable of generating quantifiable FRET (fluorescence resonance energy transfer) signals for glucose monitoring. Our experimental data showed that the engineered glucose sensor protein can generate measurable FRET signals in response to glucose concentrations varying from 25 to 800 μM. The sensor developed based on this protein had a shelf-life of up to 3 weeks. The sensor response was devoid of interference from compounds like galactose, fructose, lactose, mannose, and mannitol when tested at physiologically significant concentrations of these compounds. This new glucose sensor protein can potentially be used to develop implantable glucose sensors for continuous glucose monitoring.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997158PMC
http://dx.doi.org/10.1016/j.bios.2010.08.052DOI Listing

Publication Analysis

Top Keywords

glucose sensor
20
sensor protein
16
glucose monitoring
16
continuous glucose
12
glucose
11
sensor
7
protein
5
protein continuous
4
monitoring
4
monitoring vivo
4

Similar Publications

In the modern age, half of the population is facing various chronic illnesses due to glucose maintenance in the body, major causes of fatality and inefficiency. The early identification of glucose plays a crucial role in medical treatment and the food industry, particularly in diabetes diagnosis. In the past few years, non-enzymatic electrochemical glucose sensors have received a lot of interest for their ability to identify glucose levels accurately.

View Article and Find Full Text PDF

This study presents an innovative glucose detection platform, featuring a highly sensitive, non-enzymatic glucose sensor. The sensor integrates nickel nanowires and a graphene thin film deposited on the gate region of an extended-gate electric double-layer field-effect transistor (EGEDL-FET). This unique combination of materials and device structure enables superior glucose sensing performance.

View Article and Find Full Text PDF

Unlabelled: The hybrid closed-loop (HCL) system, Medtronic MiniMed 770G, has been available for use by Japanese individuals with type 1 diabetes mellitus since 2021. The aim of this study was to evaluate the effect of its use on glycemic variability and quality of life (QOL) in this population. This multicenter, open-label, prospective observational study included 14 Japanese individuals with type 1 diabetes mellitus treated with MiniMed 640G.

View Article and Find Full Text PDF

Mangiferin Protects Mesenchymal Stem Cells Against DNA Damage and Cellular Aging via SIRT1 Activation.

Mech Ageing Dev

January 2025

Department of Biological Science, College of Natural Science, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Republic of Korea; BK21 FOUR Education Research Group for Age-Associated Disorder Control Technology, Department of Integrative Biological Science, Chosun University, Gwangju 61452, Republic of Korea; The Basic Science Institute of Chosun University, Chosun University, Gwangju 61452, Republic of Korea. Electronic address:

The protective effects of mangiferin (MAG) against etoposide- and high glucose (HG)-induced DNA damage and aging were investigated in human bone marrow-mesenchymal stem cells (hBM-MSCs). Etoposide, a topoisomerase II inhibitor, was used to induce double-strand breaks (DSBs) in hBM-MSCs, resulting in increased genotoxicity, elevated levels of the DNA damage sensor ATM and CDKN1A, and decreased levels of the aging markers H3 and H4. MAG activated AMPK and SIRT1, thus protecting against DSB-induced damage.

View Article and Find Full Text PDF

The implanted Eversense Continuous Glucose Monitoring (CGM) System transitioned from 90- to 180- to 365-day durations marketed today. This report summarizes the 365-day clinical study. ENHANCE was a prospective, multicenter study evaluating the accuracy and safety of the Eversense 365 CGM system through 1 year in adults with diabetes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!